Distinctive genomic features of human T-lymphotropic virus type 1-related adult T-cell leukemia-lymphoma in Western populations
Caroline S. Myers(Northwestern University), Juan Carlos Ramos(University of Miami), Kenneth Ofori(Columbia University), Eli S. Williams(University of Virginia), Fina Climent, Govind Bhagat(Columbia University Irving Medical Center), José Antônio Sanches(Universidade de São Paulo), Samuel Mo(Northwestern University), Melissa Pulitzer(Memorial Sloan Kettering Cancer Center), Alejandro A. Gru(University of Virginia), Jaehyuk Choi(Northwestern University), Jonathan J. Davick(University of Iowa), Georgios Pongas(University of Miami), Brady Beltrán(Universidad de San Martín de Porres), Calvin Law(Northwestern University), Carlos Barrionuevo Cornejo(Instituto Nacional de Enfermedades Neoplásicas), Sandro Casavilca‐Zambrano(Institute for Anthropological Research), Luis Malpica(The University of Texas MD Anderson Cancer Center), Daniela Dueñas(Instituto Nacional de Enfermedades Neoplásicas), Denis Miyashiro(Peter MacCallum Cancer Centre), Maxime Battistella(Peter MacCallum Cancer Centre), Jennifer R. Chapman(University of Miami), Octavio Servitje(Bellvitge University Hospital), Cristopher A. Moskaluk(University of Virginia), Kimberley Ringbloom(Northwestern University), Luciana Barreto(University of Miami), Ngoc Toomey(University of Miami), Denisse Castro(Hospital Nacional Cayetano Heredia), Carlos Brites(Universidade Federal da Bahia)
Cited by 7
Related Papers
Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
|Journal of Clinical Oncology|2011|657
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
|The Lancet|2017|580